

**AMENDMENT TO CLAIMS**

Please amend the pending claims as follows:

1. (Withdrawn) A method for inhibiting growth or inducing cell death in a tumor cell, the method comprising the step of contacting the tumor cell with an effective amount of an anti-L1CAM antibody or L1CAM-binding fragment thereof for a time and at a concentration sufficient to inhibit cell growth or induce cell death in the tumor cell.
2. (Withdrawn) The method of claim 1, wherein the anti-L1CAM antibody is immunologically specific for human L1CAM.
3. (Withdrawn) The method of claim 1, wherein the tumor cell is a human tumor cell.
4. (Withdrawn) The method of claim 3, wherein the human tumor cell is a colon cancer cell, a cervical carcinoma cell or a breast cancer cell.
5. (Withdrawn) The method of claim 1, wherein cell death is induced in at least 50% of the tumor cells.
6. (Withdrawn) The method of claim 1, wherein cell death is induced in at least 70% of the tumor cells.
7. (Withdrawn) The method of claim 1, wherein cell death is induced in at least 90% of the tumor cells.
8. (Currently Amended) A pharmaceutical composition for the treatment of carcinoma treating a tumor cell that expresses L1CAM, the composition comprising an unconjugated anti-L1CAM antibody or L1CAM-binding fragment thereof and a pharmaceutically-acceptable excipient, wherein the antibody is not conjugated to a radionucleotide or toxin.

9. (Original) A pharmaceutical composition according to claim 8 wherein the anti-L1CAM antibody is immunologically specific for human L1CAM.